Project C
Resume:
John C. Gordon, Ph.D.
Townsend, DE 19734
**************@*****.***
Dear sir or madam:
I would like to apply for the Field Service Engineer position at Beckman Coulter. I am seeking new employment because I was recently laid off by AstraZeneca due to the closure of the Wilmington DE drug discovery site. I am trained as a biochemist and was most recently a Principal Scientist in the Lead Generation Biology section at AstraZeneca Pharmaceuticals. I believe that my biochemical/cell biology training (Ph.D. in biochemistry) and extensive hands on lab experience in pharma (50 % of my responsibilities) has given me a breadth of technical expertise. I believe that this position will enable me to achieve my objective of finding a new position in the Delaware Valley that would enable me to transition from big pharma into a technically-oriented position that draws upon my experiences. I am able to freely travel and work beeper duty and an aware that the salary will be at an entry level.
Pleas contact me to discuss my candidacy for this position. I can be reached at **************@*****.*** or by cell phone 302-***-****). My references at AstraZeneca are attached to my resume.
Sincerely,
John C. Gordon, Ph.D.
Principal Scientist
JOHN C. GORDON, PH.D.
321 Deakyneville Road
Townsend, DE 19734 **************@*****.*** Cell: 302-***-****
SUMMARY
Ion channel and GPCR receptor pharmacologist with 20 years of drug discovery experience developing cell-based and biochemical screening assays, leading cross functional drug discovery project teams and mentoring junior scientists. Recognized for in vitro assay scientific expertise and innovative solutions to drug discovery challenges, delivering targeted and relevant in vitro screening assays to project teams, working closely with medicinal chemists to drive SAR forward, and advancing projects to their next milestone transition.
• In vitro cell-based and biochemical assay development
• Lead Generation and Lead Optimization drug discovery project leadership
• Training junior scientist
• Trained in pre-clinical cGLP testing regulations
PROFESSIONAL EXPERIENCE
ASTRAZENECA PHARMACEUTICALS, Wilmington, DE 1990- Aug. 2010
Principal Scientist, Lead Generation Dept. (2001-2010)
Project leader/core team member on multiple concurrent lead generation projects. Oral and written project presentations to senior management in the US and Europe. Member of target validation teams responsible for developing lead generation strategies for new targets. Lead Generation in vitro screening discipline expert responsible for mentoring junior scientists in the implementation of new automated 96/384 well plate cellular and biochemical assays (optimization, characterization, reproducibility assessment, protocol writing, notebooks and data analysis).
• Championed two positive modulator LG projects. Discovered first D1 PAM.
• Hands-on experience developing opiate GTPgS SAR and selectivity screening assays that enabled an opiate receptor drug discovery project to advance from the lead generation phase to the lead optimization phase.
• Hands-on experience developing novel radioligand binding assays and radioligands for multiple targets (the 7 nAChR ligand-gated ion channel, microglial furosemide binding protein, and the extracellular domain of the CRF1 receptor) that were utilized by the LG and LO project teams to drive SAR, support site-directed mutagenesis studies, validate targets, support translational science plans, and nominate candidate drugs for development.
Lead Optimization Project Leader, Biology Dept. (1997-2000)
Led cross functional lead optimization project team. Designed and implemented the screening cascade for the 7 nAChR agonist project. Supervised junior in vitro screening scientists for multiple projects.
• Lead 7 nAChR agonist project team from lead generation to lead optimization phase.
• Designed protocol for the first 7 nAChR modulator FLIPR (Ca2+ flux/cell based) high throughput functional screening assay.
Senior Research Biochemist, Biology Dept. (1990-1996)
Led target validation teams. Developed tissue and cell-based in vitro compound screening assays to support lead generation and lead optimization projects.
• Proposed the first 7 nACh ligand-gated ion channel receptor agonist project for cognitive disorders and led the development of the biochemical, oocyte and cell based screening cascade.
• Discovered AR-R17779, the first subtype selective 7 nAChR agonist (US patent 5,902,814), used to validate the target for cognition indications.
• Co-discovered that marketed 5HT3R ligand-gated ion channel antagonist tropisetron was also a potent 7 nAChR agonist, providing evidence that 7 nAChR agonist activity was not a safety liability in humans.
• Developed native M1 muscarinic functional assay ([3H]PI turnover in rat hippocampal prisms) used as the physiologically relevant SAR-driving screen for an M1 agonist lead optimization project.
SCIENTIFIC AWARDS
Gateway Award. Awarded for scientific and project leadership contributions to multiple 7 nAChR agonist and positive modulator projects, including the creation of the first nicotinic receptor ion channel drug discovery project at AstraZeneca.
Breakthrough Award. Awarded for development of a novel radioligand binding assay that enabled the validation of a microglial membrane protein as an anti-inflammatory drug target for Alzheimer’s disease.
EDUCATION
B.S., Biochemistry, Pennsylvania State University, State College, PA
Ph.D., Biochemistry, Georgetown University, Washington, D.C.
Thesis: Partial purification of a water-soluble liver protein that regulates adenylate cyclase activity and cholera toxin-catalyzed ADP-ribosylation of the G protein.
POST DOCTORAL EXPERIENCE
Medical College of Virginia; Fellow, Dept. Biochemistry
Utilized monoclonal antibodies and stopped-flow fluorescence to study the effect of structure on activity of the electric ray nicotinic acetylcholine receptor. Isolated rat liver mRNA that used to clone the precursor to rat mitochondrial aspartate aminotransferase
Hershey Medical Center of Pennsylvania State University: Fellow, Dept. Biochemistry
Investigated hormonal regulation of serum albumin and phenylalanine hydroxylase expression in hepatocytes using in vitro translation of mRNA.
CONTINUING EDUCATION
Two day training in GLP for preclinical testing (2010)
PROFESSIONAL AFFILIATION
Society for Neuroscience
EXPERIMENTAL EXPERIENCE
Ion channels (nicotinic, 5-HT3, Ca ), GPCRs (muscarinic, dopaminergic, histamatergic, CRF), cellular ion channel flux assays (fluorescence, radioactive; FLIPR, stopped flow), GTPgS/SPA functional assays; radioligand binding assays, enzymatic assays (ADR transferases; adenylate cyclase, PKC, phenylalanine hydroxylase), neurotransmitter release assays (superfusion/striatal prisms), automation, tissue culture, protein purification, receptor solubilization and reconstitution, membrane isolation, organ bath, sucrose gradients; centrifugation; RIA, SDS-PAGE; Westerns, RNA isolation and in vitro translation.
INVITED EXTERNAL PRESENTATIONS
AR-R17779: A high affinity, subtype-selective full agonist of the 7 nicotinic acetylcholine receptor. (May 1999) IBC’s 2nd Int. Symp. on Nicotinic Acetylcholine Receptors- Advances in Molecular Pharmacology and Drug Development. Annapolis, MD.
AR-R17779: A subtype-selective full agonist at the rat 7 nAChR. (May 1999) Neuronal nicotinic receptors- Their functional role in CNS Disorders with Focus on New Therapeutic Implications. Huddinge, Sweden.
AR-R17779: A subtype-selective full agonist at the rat 7 nAChR. (April 2000) Sixth Int. Stockholm/Springfield Symp. on Advances in Alzheimer Therapy. Stockholm, Sweden.
PUBLICATIONS
Maier, D.L., Hill, G., Ding, M., Tuke, D., Einstein, E., Gurley, D., Gordon, J.C., Bock, M.J., Smith, J.S., Bialecki, R., Eisman, M., Elmore, C.S., and Werkheiser, J.L. (2010) Preclinical validation of a novel alpha-7 nicotinic receptor radiotracer, [3H]AZ11637326: Target localization, bio-distribution and ligand occupancy in the rat brain., Neuropharm. (submitted).
Gordon, J.C., Edwards, P.D., Elmore, C.S., Lazor, L.A., Paschetto, K.A., Bostwick, J.R., Sylvester, M.A., Maugher, R.C. and Aharony, D. (2010) [125I]Yamada peptide 20: a novel radioligand specific for the extracellular domain of the CRF1 receptor., Eur. J. Pharmac (in press).
Brugel, T.A., Smith, R.W., Balestra, M., Becker, C., Daniels, T., Koether, G.M., Throner, S.R., Panko, L.M., Brown, D.G., Liu, R., Gordon, J and Peters, M.F. (2010) SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists., Part 2. Biorg. Med. Chem Lett. 20:5405-5410.
Brugel, T. A.; Smith, R. W.; Balestra, M.; Becker, C.; Daniels, T.; Hoerter, T. N.; Koether,G. M.; Throner, S. R.; Panko, L. M.; Folmer, J. J.; Cacciola, J.; Hunter, A. M.; Liu, R.; Edwards, P. D.; Brown, D. G.; Gordon, J.; Ledonne, N. C.; Pietras, M.; Schroeder, P.; Sygowski, L. A.; Hirata, L. T.; Zacco, A.; Peters, M. F. , Discovery of 8-Azabicyclo[3.2.1]octan-3-yloxy-benzamides as Selective Antagonists of the Kappa Opioid Receptor. Part 1., Bioorg. Med. Chem. Lett. 2010, 20, 5847
Gordon, J., Phillips, E., Gurley, D., Heys, J.R., Lazor, L., Barthlow, H., Mallamaci, M., and Keith, R. (2010) In vitro binding characterization of [3H]AZ11637326, a novel 7 selective neuronal nicotinic receptor agonist radioligand., Eur. J. Pharmac. J. 645:63-69.
Sydserff, S., Sutton, E.J., Song, D., Quirk, M.C., Maciag, C., Li, C., Jonak, G., Gurley, D., Gordon, J.C., Christian, E.P., Doherty, J.J., Hudzik, T., Johnson, E., Mrzljak, L., Piser, T., Smagin, G.N., Wang, Y., Widzowski, D., Smith, J.S. (2009). Selective 7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes., Biochemical Pharmac. 78: 880-888.
Pomper, M.G., Phillips, E., Fan, H.F., McCarthy, D., Keith, R.A., Gordon, J.C., Scheffel, U., Dannals, R.F., Muschachio, J.L., (2005) Synthesis and biodistribution of radiolabeled 7 nicotinic acetylcholine receptor ligands., J. Nucl. Med. 46:326-334.
Macor, J., Gurley, D., Lanthorn, T., Loch, J., Mack, R., Mullen, G., Tran, O., Wright, N., and Gordon, J. (2001) The 5-HT3R antagonist tropisetron (ICS 205-930) is a potent and selective 7 nicotinic receptor partial agonist., Bioorg. & Med. Chem. Lett. 11:319-321.
Cox, C., Malpass, J., Gordon, J. and Rosen, A. (2001) Synthesis of epibatidine isomers: endo-5 and 6- (6’-chloro-3’-pyridyl-2-azabicyclo[2.2.1]heptanes., J. Chem. Soc., Perkin Trans. 1:2372-2379.
Mullen, G., Napier, J., Balestra, M., DeCory, T., Hale, G., Macor, J., Mack, R., Loch, J. III, Wu, E., Kover, A., Verhoest, P., Sampognaro, A., Phillips, E., Zhu, Z., Murray, R., Griffith, R., Blosser, J., Gurley, D., Machulskis, A., Zongrone, J., Rosen, A., and Gordon, J. (2000). (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5’-oxazolidinone-2’-one], a conformationally restricted analog of acetylcholine, is a highly selective full agonist at the 7 nicotinic acetylcholine receptor., J. Med. Chem. 43:4045-4050.
Levin, E.D., Bettegowda, C., Blosser, J. and Gordon, J. (1999) AR-R17779, an 7 agonist improves learning and memory in rats. Behav. Pharm. 10:675-680.
Widzowski, D.V., Bialobok, P., Kucera, K.E., Mihut, R., Sitar, S., Knowles, M., Stagnitto, M., Howell, A., McCreedy, S., Machulskis, A., Zongrone, J., Gordon, J., Marler, M., Wu, E.S.C., Mullen, G., Triggle, D.J. and Blosser, J. (1997) Development of a pharmacological target profile for muscarinic agonists., Drug Dev. Res. 40:117-132.
Wu, E.S.C., Kover, A., Loch, J.T. III, Rosenberg, L.P., Semus, S.F., Verhoest, P.R., Gordon, J.C., Machulskis, A.C., McCreedy, S.A., Zongrone, J., Blosser, J.C. (1996) Acylhydrazones as M1/M3 selective muscarinic agonists., Biorg. & Med. Chem. Lett 6:2525-2530.
Wu, E.S.C., Mack R.A., Kover, A., Loch, J.T. III, Mullen, G., Murray, R.J., Gordon, J.C., Machulskis, A.C., McCreedy, S.A., and Blosser, J.C. (1995) Synthesis and biological activity of enantiomers of a conformationally restricted muscarone analog., Biorg. & Med. Chem. Lett. 5:1813-1818.
Pinkus, L.M. and Gordon, J.C. (1991) Utilization of zacopride and its R- and S-enantiomers in studies of 5HT3 receptor "subtypes. Serotonin: Molecular Biology, Receptors and Functional Effects., Proc. of the 2nd IUPHAR Satellite Meeting on Serotonin, pgs. 439-448. Ed. Fozard, J.R. (Birkhauser).
Gordon, J.C., Sarbin, N.S., Barefoot, D.S. and Pinkus, L.M. (1990) Solubilization of a 5-HT3 binding site from rabbit small bowel muscularis membranes. Eur. J. Pharmac. 188:313-319.
Gordon, J.C.. and Rowland, H.C. (1990) Nerve growth factor induces 5-HT3 recognition sites in rat pheochromocytoma (PC12) cells., Life Sci. 46:1435-1442.
Pinkus, L.M., Sarbin, N.S., Gordon, J.C. and Munson, H.R. Jr. (1990) Antagonism of [3H]zacopride binding to 5-HT3 recognition sites by its (R) and (S) enantiomers., Eur. J. Pharmac. 179:231-235.
Gordon, J.C., Barefoot, D.S., Sarbin, N.S., and Pinkus, L.M. (1989) [3H]zacopride binding to 5-hydroxytryptamine3 sites on partially purified rabbit enteric neuronal membranes., J. Pharm. Exp. Therap. 251:962-968.
Pinkus, L.M., Sarbin, N., Barefoot, D.S. and Gordon, J.C. (1989) Association of [3H]zacopride with 5-HT3 binding sites., Eur. J. Pharmac. 168:355-362.
Mattingly, J.R., Rodriguez-Berrrocal, F.J., Gordon, J., Iriarte, A. and Martinez-Carrion, M. (1987) Molecular cloning and the in vivo expression of a precursor to rat mitochondrial aspartate aminotransferase., Biochem. Biophys. Res. Com. 149:859-865.
Gordon, J.C. and Blecher, M. (1984) Partial purification of a water soluble liver protein that regulates adenylate cyclase activity (basal, hormone, and cholera toxin-activated) and cholera toxin catalyzed ADP-ribosylation of the membrane G protein., Biochem. et Biophysica Acta 801:325-333.
KEY ABSTRACTS
Gordon, J., Hirata, l., Paschetto, K. and Wilkins, D. (2009) Comparative appraisal of GTP-Eu and 35S-GTPgS functional assays at describing the pharmacology of human mu, kappa and delta opiate receptor subtypes. G-Protein Targets Colloquium, New Orleans, LA.
Gordon, J., Hubbs, S., Stein, M., Radov, l., Greenberg, B., Zysk, J., Balestra, M., Murphy, M., Hightower, C., Mauger, R., Sylvester, M., and Edwards, P., (2004) Characterization and solubilization of a high affinity [3H]furosemide acetate binding activity from BV-2 membranes. SFN abstr. 673.4
Contact this candidate